Episode 23 - Dr. Ken Pienta:
Pinning Down Prostate Cancer
(Johns Hopkins Series Part 2)
Dr. Ken Pienta, Professor of Urology, Oncology, Pharmacology, Molecular Sciences, and Director of Research for The James Buchanan Brady Urological Institute, shares his insight on the state-of-the-art treatment and outcomes for prostate cancer. From proton therapy to immunotherapy, Johns Hopkins is leading the way in innovative ways for the treatment of this widespread disease.
In the second installment of our Johns Hopkins series, hosts Dr. Steven Taback and Bill Curtis are joined by Dr. Ken Pienta, Professor of Urology, Oncology, Pharmacology, Molecular Sciences, and Director or Research for The James Buchanan Brady Urological Institute, as he sheds light on the state of the art for treatment and outcomes of prostate cancer.
In this dedicated series, we're showcasing the medical breakthroughs & innovations from one of the world's most preeminent hospitals: Johns Hopkins Medicine.
Johns Hopkins Medicine is dedicated to improving the health of the community and the world by setting the standard of excellence in medical education, research, and clinical care.
1:46 - What is it about Johns Hopkins that continues to produce top rankings and set the gold standard for practice and research?
3:20 - Does Johns Hopkins build their own robotics systems?
4:05 - Why do so many of men still die from prostate cancer?
5:30 - With prostate cancer numbers continually so high, why not prophylactically remove the prostate?
7:35 - What are the signs men should look for that indicate prostate cancer?
8:37 - What is the efficacy of the Prostate Specific Antigen (PSA) test, and what drawbacks does it have?
13:43 - Is there a time to proceed with a biopsy without visible lesions from an MRI?
16:04 - Proton Therapy and prostate cancer
17:54 - The use of radiation and hormone type therapy on younger men with prostate cancer
18:55 - Incontinence and impotence post prostate treatment
20:30 - Are there lifestyle changes one can make to prevent prostate cancer?
21:36 - Immunotherapy and prostate cancer
22:54 - What is the state-of-the-art relative to testosterone and prostate cancer?
26:35 - How depressed are the numbers for screening prostate cancer during the COVID pandemic, and what is the fallout
to the lack of testing?
Produced & Edited by: AJ Moseley
Hosted by: Dr. Steven Taback & Bill Curtis
Sound Engineering by: Steve Reikeberg
Theme Music by: Celleste & Eric Dick